All Articles

Dycom, a leading telecommunications infrastructure provider, has appointed former Core & Main CEO Stephen LeClair to its board. The move signals a strategic emphasis on operational excellence and potential diversification.

Junior exploration company Aventis Energy is leveraging artificial intelligence to refine exploration at its promising uranium project in Saskatchewan, boosting investor confidence and driving innovation in the sector.

Alzheimer's biotech Acumen Pharma appoints industry veteran George Golumbeski as Chairman ahead of pivotal Phase 2 trial results. Analysts examine the appointment and potential conflicts.

The acquisition aims to fortify emergency communications infrastructure as 911 centers face increasing strain from cyberattacks, aging equipment, and natural disasters. AI-powered solutions are key to the future of emergency response.

A fresh influx of funding and promising clinical data fuels 4D Molecular Therapeutics' efforts to revolutionize treatment for age-related macular degeneration, diabetic macular edema and cystic fibrosis with innovative gene therapies.

Canadian healthcare firm SRx Health appoints a cannabis industry leader to its board as the company navigates significant financial challenges, raising questions about a potential strategic shift.

A new generation of flow batteries, utilizing abundant materials and existing infrastructure, aims to tackle long-duration energy storage challenges. Quino Energy's latest funding signals a major push for sustainability in the grid.

A new online directory, FintechVendors.com, is disrupting the crowded fintech landscape with a unique approach: a free, curated resource prioritizing vendor discovery and community building over lead generation and aggressive sales tactics.

The sale of Dexter Stamping’s Tennessee plant signals a broader industry shift as suppliers navigate EV transition & supply chain concerns. A deep dive into the factors driving the auction.

As the CMMC deadline looms, a new cybersecurity platform, Guardient, seeks to level the playing field for small and mid-sized defense contractors struggling with complex and costly compliance requirements.

A new collaboration aims to provide specialized cybersecurity services – including virtual SOC capabilities – to help government contractors navigate increasingly complex regulations and evolving cyber risks.

The rise of 'Know Your Customer'-free crypto casinos promises privacy and speed, but experts warn of increased risks and a lack of regulatory oversight. Is anonymity worth the potential downsides?

JAKKS Pacific’s Disguise expands its licensing deal with Aniplex for Demon Slayer, capitalizing on the anime's blockbuster success and a booming cosplay market. Details inside.

Biotech firm Protara Therapeutics is making strides with a promising cell therapy for non-muscle invasive bladder cancer and a unique treatment for a critical nutrient deficiency in patients on long-term parenteral support, bolstering its financial outlook.

Brainomix’s AI stroke imaging solution is revolutionizing care, dramatically improving patient outcomes and accelerating access to life-saving treatment, according to new data.

Private equity-backed Valor Exterior is rapidly consolidating the Northeast’s fragmented roofing and home improvement market, fueling growth through strategic acquisitions and focusing on customer satisfaction.

Israeli medtech firm Nurami Medical receives FDA clearance for its innovative dural repair graft, ArtiFascia®, and secures significant funding, positioning it for growth in the $2 billion+ global dural repair market.

South University has appointed Benjamin J. DeGweck as its new CEO and Chancellor, tasking the legal veteran with stabilizing the for-profit institution amid ongoing financial scrutiny and a recent accreditation review.

Cabaletta Bio’s innovative CAR-T cell therapy for autoimmune diseases is demonstrating encouraging clinical results, but the biotech faces significant financial challenges that cast a shadow over its future.

Data anomalies in a key clinical trial have sent Jasper Therapeutics’ stock plummeting and forced a dramatic refocus of its pipeline. A deep dive into the challenges and potential path forward.